Evidence map›Paper›PMID 38319607›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2024

Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.

Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jun TeishimaDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Takuto HaraDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Taisuke TobeDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Junichiro HirataDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Hideto UekiDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Naoto WakitaDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Yusuke ShiraishiDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Yasuyoshi OkamuraDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Yukari BandoDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Tomoaki TerakawaDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Junya FurukawaDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Ken-Ichi HaradaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yuzo NakanoDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
Masato FujisawaDepartment of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC).

methodsWe have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.

resultsThe first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.

conclusionsFrom our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.

Identifiers

PMID38319607
PMCPMC11152592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.